OQROGet OQRO Pro
Insider trade

Cg Oncology (CGON)Director sold ~$376K

James Mulay, Director at Cg Oncology, sold ~$376K of Cg Oncology shares.

~$376K
Approx. value · 12K sh @ $30.47
15K
Holds after · shares reported
Traded
Sep 5, 2025
Filed
Sep 8, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Jul 17, 2025InsiderDirector sold ~$56K of CGON shares in the open market
  2. Sep 3, 2025Insider · 2 peopleInsiders: 5 sales (~$2.8M)
  3. Sep 5, 2025 · this disclosureInsiderDirector sold ~$376K of CGON shares in the open market

What came next

  1. Sep 5, 2025Insider · 1 personInsiders: 3 sales (~$476K)
  2. Sep 11, 2025Insider · First insider buy since Jan 2024Director purchased ~$50M of CGON shares in the open market
  3. Sep 15, 2025InsiderDirector sold ~$35K of CGON shares in the open market
  4. Sep 18, 2025InsiderDirector sold ~$746K of CGON shares in the open market
  5. Sep 19, 2025InsiderDirector sold ~$139K of CGON shares in the open market
  6. Sep 29, 2025InsiderDirector sold ~$500K of CGON shares in the open market
  7. Nov 10, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On November 10, 2025, Robert Lapetina, interim principal financial and accounting officer of CG Oncology, Inc. (the “ Company ”) delivered to the Company a notice of resignation from his position as interim principal financial and accounting officer of the Company.”
  8. Nov 14, 2025Company filing · Form 8-K · ResultsReported its results
  9. Nov 22, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On November 22, 2025, the Board of Directors (the “ Board ”) of CG Oncology, Inc. (the “ Company ”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Christina Rossi to the Company’s Board, effective November 24, 2025.”
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Cg Oncology

For Cg Oncology, OQRO holds 4 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its CGON page.

Other recent filings by James Mulay, Director

The full history of James Mulay, Director is on the profile page.

How this filing works

Other disclosures at Cg Oncology

Everything OQRO holds on this company is on its CGON page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data